These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30327601)

  • 21. Examination of information release on return volatility: A market and sectoral analysis.
    Prasad M; Bakry W; Varua ME
    Heliyon; 2020 May; 6(5):e03885. PubMed ID: 32490224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Examination of National Supply-Chain Flow Time.
    Thomas D; Kandaswamy A
    Econ Syst Res; 2018; 30():. PubMed ID: 31080318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of the optimal trading model for stock investment in different industries.
    Lv D; Huang Z; Li M; Xiang Y
    PLoS One; 2019; 14(2):e0212137. PubMed ID: 30759146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereoscopic optimization of industrial structure of the equipment manufacturing industry from the perspective of collaborative emissions reduction: Evidence from China.
    Qiao B; Jiang S; Zhang J
    PLoS One; 2020; 15(4):e0232293. PubMed ID: 32353047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs of occupational injury and illness across industries.
    Leigh JP; Waehrer G; Miller TR; Keenan C
    Scand J Work Environ Health; 2004 Jun; 30(3):199-205. PubMed ID: 15250648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
    Sahoo N; Manchikanti P
    BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Communicating asset risk: how name recognition and the format of historic volatility information affect risk perception and investment decisions.
    Weber EU; Siebenmorgen N; Weber M
    Risk Anal; 2005 Jun; 25(3):597-609. PubMed ID: 16022693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. With the help of a foreign ally: biopharmaceutical innovation in India after TRIPS.
    Angeli F
    Health Policy Plan; 2014 May; 29(3):280-91. PubMed ID: 23558959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medium term planning of biopharmaceutical manufacture using mathematical programming.
    Lakhdar K; Zhou Y; Savery J; Titchener-Hooker NJ; Papageorgiou LG
    Biotechnol Prog; 2005; 21(5):1478-89. PubMed ID: 16209554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Range-based volatility, expected stock returns, and the low volatility anomaly.
    Blau BM; Whitby RJ
    PLoS One; 2017; 12(11):e0188517. PubMed ID: 29190652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How Agricultural Media Cover Safety Compared with Periodicals in Two Other Hazardous Industries.
    Marolf A; Heiberger S; Evans J; Joseph L
    J Agric Saf Health; 2017 Jan; 23(1):83-94. PubMed ID: 29140620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intellectual Capital and Financial Performance: Comparison With Financial and Pharmaceutical Industries in Vietnam.
    Zhang XB; Duc TP; Burgos Mutuc E; Tsai FS
    Front Psychol; 2021; 12():595615. PubMed ID: 33841234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea.
    Lee M
    Osong Public Health Res Perspect; 2015 Aug; 6(4):249-55. PubMed ID: 26473092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient experience and hospital profitability: Is there a link?
    Richter JP; Muhlestein DB
    Health Care Manage Rev; 2017; 42(3):247-257. PubMed ID: 27050925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmaceutical portfolio management: global disease burden and corporate performance metrics.
    Daems R; Maes E; Mehra M; Carroll B; Thomas A
    Value Health; 2014 Sep; 17(6):732-8. PubMed ID: 25236997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of global economic policy uncertainty in long-run volatilities and correlations of U.S. industry-level stock returns and crude oil.
    Yu H; Fang L; Sun B
    PLoS One; 2018; 13(2):e0192305. PubMed ID: 29420645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of capital structure on the profitability of pharmaceutical companies the case of iran.
    Mohammadzadeh M; Rahimi F; Rahimi F; Aarabi SM; Salamzadeh J
    Iran J Pharm Res; 2013; 12(3):573-7. PubMed ID: 24250664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem.
    Kurata H; Ishino T; Ohshima Y; Yohda M
    Front Bioeng Biotechnol; 2022; 10():841420. PubMed ID: 35387299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The surprising economics of a "people business".
    Barber F; Strack R
    Harv Bus Rev; 2005 Jun; 83(6):80-90, 149. PubMed ID: 15938440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.